BioLineRx in-licenses another HCV compound

BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX) announced a deal with Genoscience (Marseille, France) and RFS Pharma LLC (Tucker, Georgia) to in-license its second HCV compound in less than two weeks. BioLineRx received exclusive, worldwide rights to BL-8030, an HCV NS3 protease inhibitor in preclinical development. BioLineRx expects to begin clinical trials in 18-24 months. ...